Tatarchenko 2008.

Study characteristics
Methods	Study design: RCT Unit of randomisation: No information Total duration of study: No information Run‐in period: No information Intervention time: No information Follow‐up: No information Setting: No information
Participants	Type of heart failure: CHF, LV‐dysfunction N = 92 (ivabradine: 29, nebivolol: 33, SC: 30) Mean age: 57.3 ± 4.5 years Gender: No information Severity of condition: No information Inclusion criteria: CHF NYHA II‐III Exclusion criteria: No information Withdrawals: No information
Interventions	Intervention: Mean dose 7.5 mg twice a day Comparison: Standard care Nebivolol 5 mg/d Concomitant medications: ACE inhibitors Diuretics Aspirins Statins Nitrates on demand Excluded medications: No information
Outcomes	Outcomes and time points measured in the study: QoL Circadian indices of myocardial ischaemia Left ventricular contractility Conclusion: "Addition of ivabradin and nebivolol to combined treatment of ischemic heart disease with LV dysfunction raises efficacy of treatment."
Notes	Funding of trial: No information Notable conflicts of interest of authors: No information Contact to authors/unpublished data: No information
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Insufficient information to base judgement
Allocation concealment (selection bias)	Unclear risk	Insufficient information to base judgement
Blinding of participants and personnel (performance bias) All outcomes	High risk	Blinding impossible due to comparison with SC.
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Insufficient information to base judgement
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	Insufficient information to base judgement
Selective reporting (reporting bias)	Unclear risk	Insufficient information to base judgement
Other bias	Unclear risk	Insufficient information to base judgement